Although mutation analysis covering the entire SH3BP5 locus in other DLBCL cohorts is needed, another possibility is that the molecular mechanism of inhibition of BTK and JNK by SH3BP5 in DLBCL cells may be different from that in normal B cells. The gene discussed is MAPK8; the disease is diffuse large B-cell lymphoma.